Tyra Biosciences has reported initial phase 2 data on dabogratinib in bladder cancer, putting the biotech on course to start a registrational study next year. But the biotech’s stock fell in premarket trading after the complete response rate fell short of the level targeted by analysts.
Tyra rolls toward pivotal bladder cancer study even as midphase data deflates stock
